SCHEMBL1463353

SCHEMBL1463353

COc1ccc(C(F)(F)F)cc1NC(=O)Nc1ccccc1C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.57
GAA P10253 2/20 0.56
IDO1 P14902 1/20 0.56
POLB P06746 2/20 0.55
PKM P14618 1/20 0.55
RAF1 P04049 1/20 0.53
ALDH1A1 P00352 2/20 0.53
TSHR P16473 1/20 0.53
LMNA P02545 2/20 0.53
KDM4E B2RXH2 3/20 0.52
ATM Q13315 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C19 P33261 1/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
LPAR1 Q92633 1/20 0.51
HTT P42858 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31440788 0.89 KMT2A (0.61) MAPK14POLBRAF1ALDH1A1LMNA
SCHEMBL30667490 0.87 RAB9A (0.59) MAPK14GAAIDO1PKMRAF1
SCHEMBL379862 0.87 RAB9A (0.59) MAPK14GAAIDO1PKMRAF1
SCHEMBL8370028 0.82 GRIK1 (0.65) POLBRAF1ALDH1A1LMNAATM
SCHEMBL15229698 0.81 MEN1 (0.54) MAPK14GAAPOLBRAF1ALDH1A1
SCHEMBL1462953 0.81 MEN1 (0.77) POLBALDH1A1TSHRLMNAKDM4E
SCHEMBL18609592 0.81 LMNA (0.51) MAPK14PKMRAF1LMNAKDM4E
SCHEMBL164777 0.81 MAPT (0.57) MAPK14POLBRAF1ALDH1A1KDM4E
SCHEMBL14404019 0.81 HSP90AA1 (0.71) MAPK14POLBRAF1ALDH1A1KDM4E
SCHEMBL4247303 0.80 MEN1 (0.64) GAARAF1ALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071164-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS OLESEN SOEREN PETER 2011-03-24 US disclosed
US-7851492-B2 ERG channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2010-12-14 US disclosed
EP-1663192-B1 hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS NEUROSEARCH AS (DK) 2008-12-03 EP disclosed
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2006-12-14 US disclosed
EP-1663192-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS Poseidon Pharmaceuticals A/S (DK) 2006-06-07 EP disclosed
WO-2005023237-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO disclosed
WO-2005023238-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias KCNJ2, KCNN3, KCNE1 MAPK14 3349/4885GAA 2742/4885IDO1 3741/4885
US-20110071164-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS KCNJ2, KCNN3, KCNE1 MAPK14 3349/4885GAA 2742/4885IDO1 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.